This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech Stock Mailbag: Neoprobe

BOSTON (TheStreet) -- On Friday, May 20 from 11 a.m.to noon ET, I invite everyone to participate in the first Biotech Stock Mailbag live chat. This will be an opportunity to spend an hour discussing all things biotech and biotech investing with me.

The Biotech Stock Mailbag live chat will follow the same format as my well-received FDA advisory panel live blogs, except the focus will be on your biotech stock questions and comments. If this first live chat goes well, I'll schedule one each month.

Reminders of the May 20 biotech live chat will be posted later but for now mark your calendars and start thinking of some biotech stock topics you want to chat about.

Now onto your emails and questions:

Henry O. emails, "I recall a few months back you were going to write about Neoprobe (NEOP) but since then I haven't seen anything written by you. What do you think about the Lymphoseek results put out by the company this week? Is this a reason for you to get interested in Neoprobe now?"

Neoprobe says the phase III data released this week make a convincing case for the superiority of Lymphoseek over vital blue dye as a diagnostic tracing agent used for detecting the spread of cancer to lymph nodes. The study achieved all primary and secondary endpoints with statistical significance, and on most measures, Lymphoseek even performed better than it did in a previous phase III study.

But I'm a skeptic, everyone knows that, so I also went looking for the bear story. Is there something the Lymphoseek data are not telling us? Could Neoprobe's claim of Lymphoseek superiority over vital blue dye possibly crumble under regulatory review? It's always a good idea to know the long and short thesis of any stock you're considering buying, and, indeed, I found the short thesis on Neoprobe. More on this side of the story below.

Lymphoseek is a proprietary radioactive tracing agent designed for use during a surgical procedure known as intraoperative lymphatic mapping (ILM) or sentinel lymph node biopsy (SLNB). ILM is performed on patients during cancer surgery to determine if cancer has metastasized, or spread, from the primary tumor site into the lymph nodes. Once cancer gets into the lymphatic system, it can spread more easily to the rest of the body.

To prevent cancer from spreading, doctors perform an ILM procedure to identify which lymph nodes are closest to the tumor. Once these lymph nodes are found, doctors can remove them and test to see if they're cancerous. Most ILMs performed in the U.S. today rely on a combination of vital blue dye and an off-label radioactive tracing agent to map out lymph nodes.

Stock quotes in this article: NEOP, SPPI, CTIC, AEN, RPC, EXAS, CAH 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs